Greenwich LifeSciences, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a continued trend of net losses and increased operating expenses. The company, which is focused on developing an immunotherapy for breast cancer, reported no revenue for the periods in question. For the three months ended September 30, 2025, the net loss was approximately $4.15 million, compared to a net loss of $2.67 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss increased to approximately $11.44 million from $7.75 million in the prior year.
Operating expenses for the third quarter rose significantly, with research and development expenses increasing by 54% to $3.52 million, driven primarily by an options grant to employees and increased clinical expenses. General and administrative expenses also saw a notable rise of 49%, totaling $653,066, attributed to similar factors. For the nine-month period, research and development expenses increased by 42% to $9.63 million, while general and administrative expenses surged by 65% to $1.87 million.
As of September 30, 2025, Greenwich LifeSciences had total assets of $3.81 million, a decrease from $4.09 million at the end of 2024. The company’s cash reserves stood at $3.81 million, down from $4.09 million at the end of the previous fiscal year. Total liabilities increased slightly to $1.62 million from $1.56 million, with accounts payable and accrued interest accounting for a significant portion of this figure. The company’s stockholders’ equity decreased to approximately $2.18 million from $2.53 million at the end of 2024.
In terms of strategic developments, Greenwich LifeSciences is expanding its Phase III clinical trial, Flamingo-01, into Europe, with plans to open up to 150 sites globally. The company has also engaged in At The Market (ATM) offerings, raising approximately $6.31 million in net proceeds from the sale of common stock between January and September 2025. The company remains classified as a smaller reporting company and an emerging growth company, which allows it to take advantage of certain regulatory exemptions. Looking ahead, Greenwich LifeSciences anticipates continued net losses as it invests in clinical trials and infrastructure necessary for its product development and commercialization efforts.
About Greenwich LifeSciences, Inc.
Greenwich Lifescienses, Inc. is a biopharmaceutical company developing immunotherapies targeting HER2/neu-expressing cancers, primarily breast cancer. Its lead candidate, GLSI-100 (GP2 + GM-CSF), aims to prevent cancer recurrence through clinical-stage trials, including Phase III. The company focuses on cancer immunotherapy, leveraging immune system activation, with plans for global commercialization and strategic partnerships in oncology markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.